Connect with us

Technology

In-Vitro Diagnostics Instruments Market size is set to grow by USD 52.9 billion from 2024-2028, Growing geriatric population boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global in-vitro diagnostics instruments market size is estimated to grow by USD 52.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.29% during the forecast period. Growing geriatric population is driving market growth, with a trend towards potential opportunities for physician office laboratories (POL). However, strained laboratory budgets and lowering reimbursements affecting instrument sales poses a challenge. Key market players include Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

In-Vitro Diagnostics Instruments Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 – 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.29%

Market growth 2024-2028

USD 52.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.25

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 33%

Key countries

US, Germany, China, Canada, and UK

Key companies profiled

Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.

 

Market Driver

In-Vitro Diagnostics (IVD) instruments market growth is driven by the increasing adoption of Point of Care (POL) testing in primary and outpatient care. POL testing, particularly in infectious disease markers, cardiovascular diseases, and diabetes care, is gaining popularity due to its convenience and quick results. Portable IVD instruments are advancing technically, enabling clinicians to perform tests in-house. The CLIA testing for molecular assays in POL practices is expected to fuel market growth. However, certain regulatory aspects regarding CLIA-waived testing may impact market expansion. Despite these challenges, the global IVD instruments market is projected to experience average growth due to the increasing trend towards POL testing. 

The In Vitro Diagnostics Instruments Market is experiencing significant growth due to the rising demand for accurate and rapid medical tests. With a focus on infectious diseases such as Malaria and Chikungunya, the market is seeing increased adoption of advanced technologies like Next-Generation Sequencing (NGS) for pathogen detection. Laboratory technicians play a crucial role in this sector, handling various samples like blood, serum, plasma, urine, saliva, and tissues. Blood banks, home care settings, pharmaceutical companies, biotechnology firms, academic institutes, and non-communicable disease segments are key end-users. Infectious diseases and chronic conditions including cardiology, gastroenterology, and cancer are major application areas. The aging population and the rise of molecular diagnostics for diseases like Alzheimer’s and various cancers further fuel market expansion. In vitro diagnostics instruments offer efficiency, accuracy, and convenience in the laboratory environment, making them an essential tool for healthcare providers. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

In the In-Vitro Diagnostics Instruments Market, reimbursement policies for diagnostic testing vary across geographies and are trending downward. This puts pressure on hospitals and diagnostic laboratories to reduce expenditure on IVD instruments to maintain revenue. Workforce shortages and lost health insurance cards lead to fewer patient visits and limited testing volumes. Lean laboratories are emerging in some countries, prioritizing essential capital equipment purchases. Reduced reimbursements for certain instruments, such as SMBG in Europe and IVD instruments in the US, impact sales growth. IVD companies respond by focusing on emerging markets and adapting to market conditions. These factors are expected to restrict the growth of the global IVD Instruments Market during the forecast period.The In-Vitro Diagnostics (IVD) Instruments Market is experiencing significant growth due to advances in Next Generation Sequencing, Liquid Biopsy, and Personalized Medicine. Genetic and molecular diagnostic technologies are driving innovation in Clinical Profiles, Companion Diagnostics, and various disease areas such as Hospitals and Healthcare Facilities. IVD equipment in Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, and Cardiac Diseases are in high demand. Challenges include Norovirus, HIV, Lyme disease, and other infectious diseases. Reagents and kits, Software and Services, and Manufacturing Technology are essential components of this market. Diabetes, Oncology, Sexually Transmitted Diseases, and Geriatric Population are key applications. Distribution channels include hypermarkets, pharmacies, drug stores, online providers, standalone laboratories, and Clinical Laboratories. Tropical diseases and Endocrine Disorders are also targeted markets. High blood cholesterol, Heart Disease, Stroke, and Chronic Conditions are significant disease areas.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This in-vitro diagnostics instruments market report extensively covers market segmentation by 

Product 1.1 Immunochemistry1.2 Clinical microbiology1.3 Molecular diagnostics1.4 OthersEnd-user 2.1 Hospitals and diagnostic laboratories2.2 Academic and research institutes2.3 Home careGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Immunochemistry- The In-Vitro Diagnostics (IVD) Instruments Market’s highly automated segment of clinical laboratories holds the largest test volume compared to others. However, the demand for immunochemistry analyzers is declining in the US and Europe due to consolidation in France, late payments from Italy, Spain, and Portugal, and reductions in expenditure in the UK, France, and Germany. In contrast, the rise of rural hospitals in China and India lacking basic diagnostics infrastructure presents a growth opportunity. Over 80 immunoassay analyzer models are available, with manufacturers responding to competition through frequent new launches or analyzer upgrades. Reduced European reimbursement is attributed to delayed spending by some medical laboratories, while the Affordable Care Act (ACA) provides greater certainty for investments. IVDs, like Ortho Clinical Diagnostics’ VITROS immunodiagnostic products for HIV-1+2 detection, aid in early COVID-19 virus detection. Roche Diagnostics received FDA approval for the first HIV-1/HIV-2 qualitative test on cobas 6800/8800 systems. Innovative products and advanced technologies continue to enter the market, intensifying competition during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

In vitro diagnostics refer to medical tests conducted outside of a living organism, using samples of bodily fluids, tissues, or other specimens. These tests play a crucial role in the detection and diagnosis of various diseases, including infectious diseases such as Zika, Malaria, and Chikungunya, as well as chronic conditions like cardiovascular diseases, cancer, and endocrine disorders. The laboratory environment is essential for the accurate and reliable performance of these tests. In vitro diagnostics are used extensively in clinical laboratories to diagnose non-communicable diseases such as heart disease, stroke, high blood cholesterol, and Alzheimer’s disease. Molecular diagnostics and pathogen detection are advanced areas of in vitro diagnostics, offering rapid and accurate results for the diagnosis of various conditions. Laboratory technicians play a vital role in the collection, preparation, and analysis of samples for in vitro diagnostic tests. In vitro diagnostics are used in various medical specialties, including cardiology, gastroenterology, and neurology, to aid in the early detection and treatment of diseases.

Market Research Overview

In Vitro Diagnostics Instruments Market: Overview The In Vitro Diagnostics Instruments Market refers to the industry that produces and supplies diagnostic tools and equipment used in medical laboratories for analyzing samples derived from bodily fluids, tissues, and other specimens. These diagnostic instruments play a crucial role in detecting various diseases, including infectious diseases such as Norovirus, HIV, Lyme disease, and Shigellosis, chronic conditions like diabetes, cardiovascular diseases, cancer, and Alzheimer’s disease, and genetic disorders. The market caters to various end-users, including hospitals, healthcare facilities, pharmacies, drug stores, online providers, standalone laboratories, and clinical laboratories. The In Vitro Diagnostics Instruments Market encompasses a wide range of diagnostic technologies, including Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and others. The market is segmented into various product categories, including IVD equipment, Diagnostic Technologies, Reagents and Kits, Software and Services, and Molecular Diagnostics. Molecular Diagnostics further includes Next-Generation Sequencing (NGS), Liquid Biopsy, and Personalized Medicine. The market is also influenced by various factors such as the aging population, the rise in non-communicable diseases, and the increasing prevalence of chronic conditions. The In Vitro Diagnostics Instruments Market is driven by the growing demand for early and accurate diagnosis, the increasing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies such as NGS, liquid biopsy, and companion diagnostics. The market is also expected to witness significant growth due to the increasing prevalence of diseases such as diabetes, cancer, and cardiovascular diseases, and the growing awareness and acceptance of genetic testing. The market is highly competitive, with various players offering a wide range of diagnostic instruments and solutions. The market is also witnessing significant innovation, with new technologies and products being developed to address the evolving needs of healthcare providers and patients. Some of the key trends in the market include the increasing use of automation, the integration of artificial intelligence and machine learning, and the growing focus on point-of-care testing. The In Vitro Diagnostics Instruments Market is expected to grow at a significant CAGR during the forecast period, driven by the increasing demand for accurate and timely diagnosis, the growing prevalence of chronic diseases, and the increasing adoption of advanced diagnostic technologies. The market is also expected to be influenced by various factors such as regulatory frameworks, reimbursement policies, and technological advancements. In conclusion, the In Vitro Diagnostics Instruments Market plays a vital role in the healthcare industry by providing accurate and timely diagnosis, enabling personalized medicine, and contributing to better patient outcomes. The market is highly dynamic and is expected to witness significant growth in the coming years, driven by various factors such as the increasing prevalence of chronic diseases, the growing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductImmunochemistryClinical MicrobiologyMolecular DiagnosticsOthersEnd-userHospitals And Diagnostic LaboratoriesAcademic And Research InstitutesHome CareGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-vitro-diagnostics-instruments-market-size-is-set-to-grow-by-usd-52-9-billion-from-2024-2028–growing-geriatric-population-boost-the-market-technavio-302210037.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets

Published

on

By

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform

TOKYO, April 14, 2025 /PRNewswire/ — PRISM BioLab, Co. Ltd. (“PRISM BioLab”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc. (“Elix”), effective April 1, 2025.

This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab’s proprietary peptide mimetic technology for controlling protein-protein interactions with Elix’s cutting-edge AI drug discovery platform.

In drug discovery, generating a clinical candidate molecule typically takes long time and requires synthesis of hundreds to thousands of compounds, making research and development efficiency a critical challenge. Through this partnership, PRISM BioLab’s proprietary small molecule peptide-mimetic PepMetics® technology will be integrated with Elix’s AI drug discovery platform “Elix Discovery™.” This collaboration will expand the AI search range to include previously unconsidered small molecules, enabling efficient identification of promising compounds for traditionally difficult targets and accelerating the creation of breakthrough drug candidates. By leveraging both companies’ AI capabilities and medicinal chemistry expertise, the partnership aims to reduce time and costs and improve success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs.

Comments from Executives

Elix co-founder and CEO Shinya Yuki, Ph.D.:

In our previous pilot project with PRISM BioLab, we achieved breakthrough results by creating novel compound candidates with an efficiency that would be unimaginable using conventional approaches. This success clearly demonstrated that the combination of our companies’ technologies and expertise holds tremendous potential in drug discovery. I am genuinely looking forward to this business partnership, where we can leverage our complementary strengths to pursue outcomes that neither company could achieve alone.

PRISM BioLab CEO Dai Takehara:

As we challenge ourselves to ‘create new areas of drug discovery’ with peptide-mimetic small molecules, AI utilization is essential. We expect our efforts to be significantly accelerated through collaboration with Elix, whose mission is to ‘rethink drug discovery.’ Our pilot project has already demonstrated the synergistic effect of our technologies and team collaboration, and we will continue to pursue the early creation of groundbreaking new drugs together.

PRISM BioLab CTO Tatsuya Toma Ph.D.:

Improving drug discovery efficiency is an eternal challenge. Delivering better medicines to patients and healthcare professionals as quickly as possible requires innovation. Our PepMetics® technology has characteristics that are highly compatible with AI applications. Elix is not only a professional in AI and machine learning but also expanding their knowledge and understanding of drug discovery while maintaining a flexible corporate culture. They have shown great interest in PepMetics® features, and I believe we can advance comprehensive drug discovery research together, leveraging PepMetics® characteristics to accelerate the process.

About Elix

Elix is an AI drug discovery company with the mission of “Rethinking drug discovery”. Through their flagship software platform, Elix Discovery™, and collaborative consulting engagements, they work with leading pharmaceutical companies and biotech startups to reduce the enormous costs and time associated with drug discovery, while improving the rate of successful outcomes. They achieve these goals via their company’s unique blend of AI engineering and medicinal chemistry expertise that allows them to stay at the forefront of development in both fields, and offer the solutions of tomorrow to the problems of today.

https://www.elix-inc.com/ 

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceutical Co., Ltd. are in clinical development for cancer and liver disease, respectively.

www.prismbiolab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/prism-biolab-and-elix-join-forces-to-accelerate-ai-driven-drug-discovery-for-protein-protein-interaction-targets-302426497.html

SOURCE PRISM BioLab Co., Ltd.

Continue Reading

Technology

RIAD Corp. reveals AI-powered hotel group booking platform Ria at ITB Berlin 2025

Published

on

By

BERLIN, April 14, 2025 /PRNewswire/ — Riad Corporation, a leading AI-powered travel technology company, successfully launched its flagship product, RIA 1.0, at ITB Berlin 2025, one of the world’s largest travel trade shows. The company attracted over 300 visitors to its booth and secured 150 enterprise client sign-ups during the three-day event, marking a major milestone for its global expansion.

RIA 1.0 is an advanced AI platform that fully automates group hotel reservations, tailored for travel agencies and corporate clients handling complex requirements. Unlike traditional systems, RIA enables both direct bookings and customized group requests, processed entirely by AI without manual work. The platform simplifies large-scale, multi-hotel bookings — tasks that usually take days — completing them in minutes.

During ITB Berlin, Riad Corporation presented live demonstrations showing how RIA’s AI engine handles diverse, high-volume booking scenarios. Attendees praised its intuitive interface, seamless integration, and real-time responses to specific client needs, including corporate events, MICE bookings, and incentive groups.

Mike Lee, CEO of Riad Corporation, commented, “Meeting so many global partners at ITB Berlin was truly meaningful, and we are proud to showcase our technology to the world,” adding, “We will continue to focus on R&D to deliver stronger innovations and achieve greater success globally.”

In addition, Riad Corporation announced plans to launch AI-based group flight booking services later this year, transforming RIA into a comprehensive group travel platform covering both hotels and flights.

RIA has already gained momentum in Southeast Asia, with over 800 enterprise clients, and aims to reach 2,000 clients by the end of 2025.

Riad Corporation’s strong debut at ITB Berlin reflects rising demand for AI-driven solutions in travel. As group travel grows more complex, RIA 1.0 is positioned to lead the market with unmatched speed, accuracy, and automation.

For more information about Riad’s solution RIA, visit ‘www.ria-travel.com‘.

Photo – https://mma.prnewswire.com/media/2646943/ria.jpg
Logo – https://mma.prnewswire.com/media/2646944/RIAD_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/riad-corp-reveals-ai-powered-hotel-group-booking-platform-ria-at-itb-berlin-2025-302424402.html

Continue Reading

Technology

GameChange Solar Closes FY 25 in India with Strong Order Momentum

Published

on

By

Order bookings exceed 7 GW in FY25Total India projects (commissioned as well as under installation) cross 13 GWOver 20 GW local manufacturing capacity for key components

BENGALURU, India , April 14, 2025 /PRNewswire/ — GameChange Solar, a leading global supplier of solar tracker and fixed-tilt racking technology, has closed FY 25 on a strong note in the Indian market, with total order bookings of 7 GW. Of this, nearly 2 GW of tracker orders were signed in Q4 FY 25, marking a robust end to the financial year.

With this milestone, GameChange Solar’s total projects in India (commissioned as well as under installation) have now exceeded 13 GW, reinforcing its position as a trusted technology partner in the country’s growing utility-scale solar segment. A significant portion of these new orders represents repeat business from clients, reflecting GameChange Solar’s proven performance, consistent execution, and customer-first approach.

To support this growth, the company’s local manufacturing capacity for key components has surpassed 20 GW annually, enabling faster deliveries and stronger alignment with project timelines.

India continues to be one of the most exciting and dynamic solar markets globally, and this strong finish to FY 25 reflects the valued relationships we’ve built with our customers and the reliability of our Genius Tracker™ systems,” said Vikas Bansal, President – International at GameChange Solar. “What’s particularly encouraging is the consistency of demand across states, developer profiles, and project sizes – from first-time engagements to repeat orders. It shows that the market isn’t just growing, it’s maturing, and there’s a clear preference for scalable, execution-focused partners who can deliver at speed.”

GameChange Solar’s Genius Tracker™ solutions are engineered for high-wind, high-heat environments – combining speed, structural durability, and precision tracking to maximize output and reduce project timelines. Their versatility makes them ideally suited for India’s diverse terrains and aggressive commissioning schedules.

For more information about GameChange Solar and its solar tracking solutions, visit www.gamechangesolar.com

About GameChange Solar

GameChange is the second largest global provider of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 43 GW of solar tracker and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun’s movement across the sky and optimize plant performance while protecting the array from damaging weather conditions.

Media Contact

Nisha Wadhwani

Lead – Marketing, GameChange Solar

nisha.wadhwani@gamechangesolar.com

Logo – https://mma.prnewswire.com/media/1592922/GameChange_Solar_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/gamechange-solar-closes-fy-25-in-india-with-strong-order-momentum-302426929.html

Continue Reading

Trending